Variation in leukocyte subset concentrations affects calcineurin activity measurement: Implications for pharmacodynamic monitoring strategies

Clinical Chemistry

Volumn 54, Issue 3, 2008, Pages 517-524

  Van Rossum, Huub H ^a   Romijn, Fred P H T M ^a   Sellar, Kathryn J ^a   Smit, Nico P M ^a   Van Der Boog, Paul J M ^a   De Fijter, Johan W ^a   Van Pelt, Johannes ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD ANALYSIS; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; DRUG DETERMINATION; DRUG MONITORING; DRUG URINE LEVEL; FEMALE; GRAFT RECIPIENT; GRANULOCYTE; HUMAN; IC 50; IN VITRO STUDY; KIDNEY DONOR; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LEUKOCYTE COUNT; LEUKOCYTE MIGRATION INHIBITION; LIVING DONOR; MALE; MONOCYTE; NATURAL KILLER T CELL; SPECTROMETRY; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, CD4; ANTIGENS, CD8; B-LYMPHOCYTES; CALCINEURIN; CYCLOSPORINE; DRUG MONITORING; FEMALE; GRANULOCYTES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MONOCYTES; T-LYMPHOCYTES;

EID: 40449093233     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.097253     Document Type: Article

References (35)

1. Batiuk TD, Kung L, Halloran PF. Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. J Clin Invest 1997;100:1894-901.
2. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporine-A and Fkbp-Fk506 complexes. Cell 1991;66:807-15.
3. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005;80:S254-S264.
4. Paul LC, de Fijter JH. Cyclosporine-induced renal dysfunction. Transplant Proc 2004;36:224S-8S.
5. Ponticelli C, Campise MR. Neurological complications in kidney transplant recipients. Journal of Nephrology 2005;18:521-8.
6. Taylor AL, Watson CJE, Bradley JA. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Critical Rev in Oncology Hematology 2005;56:23-46.
7. van Hooff JP, Christiaans MH, van Duijnhoven EM. Tacrolimus and posttransplant diabetes mellitus in renal transplantation. Transplantation 2005;79:1465-9.
8. Holt DW. Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Curr Opin Nephrol Hypertens 2002;11:657-63.
9. Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem 2001;34:9-16.
10. Cremers SC, Scholten EM, Schoemaker RC, Lentjes EG, Vermeij P, Paul LC, et al. A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients. Nephrol Dial Transplant 2003;18:1201-8.
11. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve - Its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999;68:55-62.
12. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-29.
13. Hesselink DA, van Gelder T, van Schaik RHN. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 2005;6:323-37.
14. Blumenthal DK, Takio K, Hansen RS, Krebs EG. Dephosphorylation of cAMP-dependent protein-kinase regulatory subunit (type-II) by calmodulin-dependent protein phosphatase: determinants of substrate-specificity. J Biol Chem 1986;261:8140-5.
15. Blanchet B, Hulin A, Duvoux C, Astier A. Determination of serine/threonine protein phosphatase type 2B PP2B in lymphocytes by HPLC. Anal Biochem 2003;312:1-6.
16. Enz A, Shapiro G, Chappuis A, Dattler A. Nonradioactive assay for protein phosphatase 2B (calcineurin) activity using a partial sequence of the subunit of cAMP-dependent protein kinase as substrate. Anal Biochem 1994;216:147-53.
17. Fukudo M, Yano I, Masuda S, Fukatsu S, Katsura T, Ogura Y, et al. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. Clin Pharmacol Ther 2005;78:168-81.
18. Koefoed-Nielsen PB, Karamperis N, Jorgensen KA. Validation of the calcineurin phosphatase assay. Clin Chem 2004;50:2331-7.
19. Sellar KJ, van Rossum HH, Romijn FPHT, Smit NPM, de Fijter JW, van Pelt J. Spectrophotometric assay for calcineurin activity in leukocytes isolated from human blood. Anal Biochem 2006;358:104-10.
20. Johnston A, Holt DW. Therapeutic drug monitoring of immunosuppressant drugs. Br J Clin Pharmacol 1999;47:339-50.
21. Jorgensen KA, Koefoed-Nielsen PB, Karamperis N. Calcineurin phosphatase activity and immunosuppression: a review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand J Immunol 2003;57:93-8.
22. Caruso R, Perico N, Cattaneo D, Piccinini G, Bonazzola S, Remuzzi G, Gaspari F. Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients. Clin Chem 2001;47:1679-87.
23. Fukudo M, Yano I, Masuda S, Okuda M, Inui K. Distinct inhibitory effects of tacrolimus and cyclosporin A on calcineurin phosphatase activity. J Pharmacol Exp Ther 2005;312:816-25.
24. Fukudo M, Yano L, Masuda S, Katsura T, Ogura Y, Oike F, et al. Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant patients: twice daily vs. once daily dosing. Liver Transpl 2006;12:292-300.
25. Batiuk TD, Pazderka F, Enns J, DeCastro L, Halloran PF. Cyclosporine inhibition of calcineurin activity in human-leukocytes in-vivo is rapidly reversible. J Clin Invest 1995;96:1254-60.
26. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999;68:1356-61.
27. Koefoed-Nielsen PB, Gesualdo MB, Poulsen JH, Jorgensen KA. Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. Am J Transpl 2002;2:173-8.
28. Koefoed-Nielsen PB, Karamperis N, Hojskov C, Poulsen JH, Jorgensen KA. The calcineurin activity profiles of cyclosporin and tacrolimus are different in stable renal transplant patients. Transpl Int 2006;19:821-7.
29. Piccinini G, Gaspari F, Signorini O, Remuzzi G, Perico N. Recovery of blood mononuclear cell calcineurin activity segregates two populations of renal transplant patients with different sensitivities to cyclosporine inhibition. Transplantation 1996;61:1526-31.
30. Sanquer S, Schwarzinger M, Maury S, Yakouben K, Rafi H, Pautas C, et al. Calcineurin activity as a functional index of immunosuppression after allogeneic stem-cell transplantation. Transplantation 2004;77:854-8.
31. Blanchet B, Hulin A, Ghaleh B, Giraudier S, Jouault H, Astier A. Distribution of calcineurin activity in blood cell fractions and impact of tacrolimus inhibition. Fundam Clin Pharmacol 2006;20:137-44.
32. Kung L, Batiuk TD, Palomo-Pinon S, Noujaim J, Helms LM, Halloran PF. Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine. Am J Transpl 2001;1:325-33.
33. Koefoed-Nielsen PB, Karamperis N, Jorgensen KA. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients. Transpl Proc 2005;37:1736-8.
34. Hartel C, Fricke L, Schumacher N, Kirchner H, Muller-Steinhardt M. Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: a quantitative measure of the efficacy of cyclosporin A-based immunosuppression. Clin Chem 2002;48:2225-31.
35. Glander P, Braun KP, Hambach P, Bauer S, Mai I, Roots I, et al. Non-radioactive determination of inosine 5′-monophosphate dehydrogenase (IMPDH) in peripheral mononuclear cells. Clin Biochem 2001;34:543-9.